New Gene Patent Rules - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

New Gene Patent Rules
The US Supreme Court's Myriad decision satisfied both patient groups and patent holders. Includes bonus online coverage.


Pharmaceutical Technology
Volume 37, Issue 8, pp. 14-16

REFERENCES
1. Myriad Gentics product information, http://www.myriad.com/products/bracanalysis/, accessed on June 23, 2013.
2. The seven patents referenced in the lawsuit are U.S. Patent Nos. 5,747,282; 5,837,492; 5,693,473; 5,709,999; 5,710,001; 5,753,441; and 6,033,857.
3. M. Yoon, J.Marshall Rev. Intell. Prop. L., 9; 953, 958 (2010).
4. Plaintiffs' Compliant filed in the US District Court, Southern District of New York, http://www.aclu.org/, accessed on July 1, 2013.
5. Defendants' Memorandum in Reply to Plaintiffs' Opposition to Myriad Defendants' Motion for Summary Judgment, http://www.pubpat.org/, accessed on July 1, 2013.
6. Bilski v. Kappos, 130 S. Ct. 3218, 3225 (2010) (citing Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980)).
7. Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. __, __ (2013) (Slip Opinion at page 5).
8. C. Brinckerhoff, "A Look at the Myriad Gene Patent Claims and the USPTO Memo to Examiners on Myriad", PharmaPatents blog, June 17, 2013, http://www.pharmapatentsblog.com/, accessed on July 1, 2013.
9. Association for Molecular Pathology v. The U.S. Patent and Trademark Office, 702 F. Supp.2d 181 (SDNY 2010).
10. Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 132 S.Ct. 1794 (2012).
11. Association for Molecular Pathology v. Myriad Genetics, Inc. 689 F.3d 1303, 1325 (Fed. Cir. 2012), aff'd in part and rev'd in part, 133 S. Ct. 2107 (2013).
12. USPTO memorandum, http://www.uspto.gov/patents/law/exam/myriad_20130613.pdf, accessed on July 1, 2013.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here